Discover the latest updates in breast cancer clinical practice and research from leading experts at the 18th St. Gallen International Breast Cancer Conference 2023 featuring key topics in early breast cancer, including immunology, the role of genomics for disease monitoring and risk stratification, as well as the anticipated St. Gallen International Consensus Session.

BCC 2023

18th St.Gallen International Breast Cancer Conference 2023
15–18 March 2023 | Vienna, Austria
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 Marleen Kok (@lab_kok) of @NKI_nl talks on multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer

Watch: 👉http://ow.ly/KGgk50NnI0B👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638229021719666697Retweet on Twitter 1638229021719666697Like on Twitter 16382290217196666972Twitter 1638229021719666697
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 | If you were interested in Enrico Franceschi’s (@AUSLBologna) talk on #medulloblastoma, watch our exclusive interview with him on overcoming resistance and the need to preserve fertility in patients!

http://ow.ly/H4XS50NnJAf

@myESMO #btsm

Reply on Twitter 1638128900587790336Retweet on Twitter 1638128900587790336Like on Twitter 16381289005877903364Twitter 1638128900587790336
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 @evaciruelos of Hospital 12 de Octubre talks on unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Watch: 👉http://ow.ly/P2rn50NmZNc👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638114521540599809Retweet on Twitter 16381145215405998091Like on Twitter 16381145215405998092Twitter 1638114521540599809
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 continues, and we’ve already been speaking with experts about their research ⚗️🔬

Make sure to keep an eye out on http://VJOncology.com for key updates in the field of #rarediseases & #sarcoma!

@VJOncology @myESMO #scmsm

Reply on Twitter 1638088395002990596Retweet on Twitter 16380883950029905961Like on Twitter 1638088395002990596Twitter 1638088395002990596
VJOncologyVJ Oncology@VJOncology·
March 20, 2023

🎥 @stolaney1 of @DanaFarberNews talks on conducting clinical trials in countries that are unlikely to be able to afford innovative drugs

Watch: 👉http://ow.ly/Cr4g50NmZpj👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1637871667958390806Retweet on Twitter 16378716679583908064Like on Twitter 163787166795839080611Twitter 1637871667958390806
Load More

BCC 2023

18th St.Gallen International Breast Cancer Conference 2023
15–18 March 2023 | Vienna, Austria
Discover the latest updates in breast cancer clinical practice and research from leading experts at the 18th St. Gallen International Breast Cancer Conference 2023 featuring key topics in early breast cancer, including immunology, the role of genomics for disease monitoring and risk stratification, as well as the anticipated St. Gallen International Consensus Session.
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 Marleen Kok (@lab_kok) of @NKI_nl talks on multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer

Watch: 👉http://ow.ly/KGgk50NnI0B👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638229021719666697Retweet on Twitter 1638229021719666697Like on Twitter 16382290217196666972Twitter 1638229021719666697
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 | If you were interested in Enrico Franceschi’s (@AUSLBologna) talk on #medulloblastoma, watch our exclusive interview with him on overcoming resistance and the need to preserve fertility in patients!

http://ow.ly/H4XS50NnJAf

@myESMO #btsm

Reply on Twitter 1638128900587790336Retweet on Twitter 1638128900587790336Like on Twitter 16381289005877903364Twitter 1638128900587790336
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

🎥 @evaciruelos of Hospital 12 de Octubre talks on unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Watch: 👉http://ow.ly/P2rn50NmZNc👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1638114521540599809Retweet on Twitter 16381145215405998091Like on Twitter 16381145215405998092Twitter 1638114521540599809
VJOncologyVJ Oncology@VJOncology·
March 21, 2023

#ESMOSarcomaandrarecancers23 continues, and we’ve already been speaking with experts about their research ⚗️🔬

Make sure to keep an eye out on http://VJOncology.com for key updates in the field of #rarediseases & #sarcoma!

@VJOncology @myESMO #scmsm

Reply on Twitter 1638088395002990596Retweet on Twitter 16380883950029905961Like on Twitter 1638088395002990596Twitter 1638088395002990596
VJOncologyVJ Oncology@VJOncology·
March 20, 2023

🎥 @stolaney1 of @DanaFarberNews talks on conducting clinical trials in countries that are unlikely to be able to afford innovative drugs

Watch: 👉http://ow.ly/Cr4g50NmZpj👈

@SG_BCC #SGBCC2023 #BCSM #BreastCancer

Reply on Twitter 1637871667958390806Retweet on Twitter 16378716679583908064Like on Twitter 163787166795839080611Twitter 1637871667958390806
Load More
Reducing inequties in women’s health 1:46
Reducing inequties in women’s health
Benjamin Anderson • 17 Mar 2023
3 pillars of the WHO Global Breast Cancer Initiative (GBCI) 2:47
3 pillars of the WHO Global Breast Cancer Initiative (GBCI)
Benjamin Anderson • 17 Mar 2023
WHO Global Breast Cancer Initiative (GBCI): improving outcomes in low- and middle-income countries 1:05
WHO Global Breast Cancer Initiative (GBCI): improving outcomes in low- and middle-income countries
Benjamin Anderson • 17 Mar 2023
Axillary dissection vs radiation for residual nodal disease after neoadjuvant systemic therapy 1:49
Axillary dissection vs radiation for residual nodal disease after neoadjuvant systemic therapy
Orit Kaidar-Person • 18 Mar 2023
What to do in patients with early-stage TNBC who have not achieved a pCR? 1:27
What to do in patients with early-stage TNBC who have not achieved a pCR?
Hope S. Rugo • 17 Mar 2023
Optimal neoadjuvant and adjuvant therapy for patients with early TNBC 5:21
Optimal neoadjuvant and adjuvant therapy for patients with early TNBC
Hope S. Rugo • 17 Mar 2023
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO 1:08
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
Marleen Kok • 16 Mar 2023
Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)? 1:49
Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
Lisa Carey • 17 Mar 2023
Personalizing approaches in early-stage TNBC 0:58
Personalizing approaches in early-stage TNBC
Marleen Kok • 16 Mar 2023
Long-term evidence for partial breast irradiation in early breast cancer 0:41
Long-term evidence for partial breast irradiation in early breast cancer
Icro Meattini • 16 Mar 2023
Remaining questions regarding the use of frontline CDK4/6 inhibitors and endocrine therapy 2:07
Remaining questions regarding the use of frontline CDK4/6 inhibitors and endocrine therapy
Sara Tolaney • 17 Mar 2023
De-escalation of radiation therapy after primary systemic therapy in non-metastatic breast cancer 0:54
De-escalation of radiation therapy after primary systemic therapy in non-metastatic breast cancer
Icro Meattini • 16 Mar 2023
Important considerations in the management of HR+, HER2-negative early breast cancer 2:05
Important considerations in the management of HR+, HER2-negative early breast cancer
Sara Tolaney • 17 Mar 2023
Why are we conducting clinical trials in countries that are unlikely to afford novel drugs? 3:08
Why are we conducting clinical trials in countries that are unlikely to afford novel drugs?
Sara Tolaney • 17 Mar 2023
Controversies in the treatment of the axilla 0:28
Controversies in the treatment of the axilla
Philip Poortmans • 16 Mar 2023
Optimizing treatment in patients with early-stage HER2-positive breast cancer 4:12
Optimizing treatment in patients with early-stage HER2-positive breast cancer
Hope S. Rugo • 17 Mar 2023
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals